Browsing Tag
ABO2203
1 post
Why Novartis is paying $575m upfront for an mRNA immune-reset bet worth up to $7.8bn
Novartis has agreed to license Abogen Biosciences’ mRNA-encoded T-cell engager ABO2203 and secure options over additional RNA programs, committing $575 million upfront while leaving most of the headline $7.8 billion value contingent on future development, regulatory and commercial milestones.